Reconstruction of the lower lip after broad oncologic resection by Colmenero flap: a reliable option

xlomafota13 shared this article with you from Inoreader Reconstruction of the lower lip after broad oncologic resection by Colmenero flap: a reliable option Via Acta Otorhinolaryngol Ital Acta Otorhinolaryngol Ital. 2021 Nov 26. doi: 10.14639/0392-100X-N1458. Online ahead of print. ABSTRACT OBJECTIVE: Reconstruction of the lower lip is complex. The Colmenero flap is an effective albeit rarely described method for the repair of medium- to large-sized defects of the lower lip. METHODS: A retrospective review was carried out using data gathered from patients who had undergone Colmenero flap reconstruction of the lower lip at our centre between 2015 and 202 0. We analysed demographic, histologic and anatomic variables as well as surgical results. This review assessed flap functionality based on proper mouth closure, absence of microstomia and oral competence. RESULTS: Thirteen Colmenero flaps were performed in 9 patients, with the flap being used bilaterally in four cases. All patients had squamous cell carcinoma of the lower lip. The mean length of the reconstructed defect was 4.1 cm (ranging between 3-7.5 cm). None of the flaps exhibited signs of necrosis. Five patients required minor surgical touch up during the second procedure: two for dehiscence, two for oral leakage and one for esthetic improvement. All patients had excellent functional and aesthetic final outcomes. CONCLUSIONS: The Colmenero flap is a good resource for medium- and large-sized lower lip reconstructions due to its reliability, limited complications, and good aesthetic and functional results. PMID:34825668 | DOI:10.14639/0392-100X-N1458 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Introducing a modified algorithm for enhanced operator independency in auditory steady-state responses (ASSRs) testing

xlomafota13 shared this article with you from Inoreader Introducing a modified algorithm for enhanced operator independency in auditory steady-state responses (ASSRs) testing Via Acta Otorhinolaryngol Ital Acta Otorhinolaryngol Ital. 2021 Nov 26. doi: 10.14639/0392-100X-N1640. Online ahead of print. NO ABSTRACT PMID:34825670 | DOI:10.14639/0392-100X-N1640 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Leader manipulator with hand rest function for microsurgery

xlomafota13 shared this article with you from Inoreader Leader manipulator with hand rest function for microsurgery Via The International Journal of Medical Robotics and Computer Assisted Surgery Abstract: Background Hand rest assists microsurgeons with maintaining a stable hand condition. In manipulating a surgical robot using teleoperation, the external hand rest poses mechanical difficulties such as interferences from manipulators. Methods Herein, we introduced hand rest functionality into a leader manipulator. The hand rest function was realized by switching the impedance value in admittance control for the translation section. With teleoperation, we evaluated the positioning accuracy in the direction of gravity and the manipulating conditions during precise positioning. Results The experiments proved that the position of the hand rest could be arranged at the intended position, and the condition with the hand rest function, applying sufficiently high impedance, and not constraining the hand rest completely provided the best performance. Conclusion Our leader manipulator showed the potentials to improve the quality of robotic microsurgery with the advantage in fine manipulation based on large repositionable working range of the hand rest. This article is protected by copyright. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Relationship between Ideal Cardiovascular Health Metrics and Hearing Loss: A 10‐Year Retrospective Cohort Study

xlomafota13 shared this article with you from Inoreader Relationship between Ideal Cardiovascular Health Metrics and Hearing Loss: A 10‐Year Retrospective Cohort Study Via Clinical Otolaryngology ABSTRACT Objective The role of ideal cardiovascular health (CVH) metrics in developing hearing loss remains uncertain. Thus, our objective was to analyze the connection between hearing loss and ideal CVH metrics in a 10-year retrospective cohort. Study Design Retrospective cohort study. Setting A health management center in Taiwan. Participants Participants who underwent the first annual health check-up between 2000 and 2006 and with a follow-up check-up more than ten years later. Main outcome measures Hearing thresholds were measured at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz. Individuals with a best ear pure-tone audiometry four-frequency average of >25 dB HL were defined as having hearing loss. The ideal CVH metrics were classified into 7 categories based on the American Heart Association's definition. The associations of hearing loss with the sum of the ideal CVH metrics and each ideal CVH metric were examined by multiple logistic regression analysis. Results The present study consisted of 6,974 participants. The 10-year follow-up showed that the odds ratio (OR) of hearing loss was 0.74 for participants with 5-7 ideal CVH metrics (95% CI, 0.59-0.93, p=0.01) compared to those with 0-2 ideal CVH metrics. Among the CVH metrics, participants with an ideal smoking status might have reduced odds of developing hearing loss; the OR was 0.72 (95% CI, 0.58-0.89, p=0.003). Conclusions Participants with an increased number of ideal CVH metrics and better performance on the smoking metric had a significantly protective effect regarding hearing loss development. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Placental-Cadherin, a biomarker for local immune status and poor prognosis among patients with tongue squamous cell carcinoma

xlomafota13 shared this article with you from Inoreader Placental-Cadherin, a biomarker for local immune status and poor prognosis among patients with tongue squamous cell carcinoma Via http://link.springer.com/journal/405,European archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino Eur Arch Otorhinolaryngol. 2021 Nov 26. doi: 10.1007/s00405-021-07181-x. Online ahead of print. ABSTRACT BACKGROUND: The prognostic and clinicopathological value of placental-Cadherin (CDH3) in multiple cancers is controversial. The diagnostic significance and functional mechanism of CDH3 in tongue squamous cell carcinoma (TSCC) have not been thoroughly investigated. This study aims to clarify the potential of CDH3 as biomarker for TSCC. METHODS: Here, meta-analysis, bioinformatics, along wet-lab techniques were employed to evaluate the diagnostic, as well as the prognostic value of CDH3 in diverse types of cancers, especially TSCC. Meta-analysis was used to determine the influence of CDH3 on prognostic and clinicopathological features in numerous cancers. Molecular biology function was used to investigate the role of CDH3 in TSCC cells. The relationship of CDH3 with tumor-infiltrating immune cells (TIICs) in TSCC was assessed us ing CIBERSORT. Moreover, gene set enrichment analysis (GSEA) was done based on TCGA. Besides, the hub genes and associated cascades were uncovered based on gene co-expression with CDH3. RESULTS: CDH3 upregulation correlated with worse overall survival and disease-free survival in various cancers. CDH3 was validated as an independent risk factor for HNSC and was linked to the onset of tumors, tumor stage, and infiltration depth. CDH3 silencing inhibited cell growth and induced apoptosis of the CAL-27 cell line. CDH3 expression level correlated with infiltration by macrophages, T cells, T cell regulatory cells (Tregs), and plasma cells in TSCC. GSEA revealed that CDH3 influences multiple cancer-associated cascades. Besides, CBX3, CCHCR1, along NFYC were identified as the core hub genes for CDH3. CONCLUSION: We identified CDH3 as a pan-cancer gene with potential prognostic and diagnostic significance in various cancers, particularly in TSCC, where it is tumorigenic. P MID:34825969 | DOI:10.1007/s00405-021-07181-x View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Cochleovestibular involvement in patients with Fabry disease: data from the multicenter cohort FFABRY

xlomafota13 shared this article with you from Inoreader Cochleovestibular involvement in patients with Fabry disease: data from the multicenter cohort FFABRY Via http://link.springer.com/journal/405,European archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino Eur Arch Otorhinolaryngol. 2021 Nov 26. doi: 10.1007/s00405-021-07173-x. Online ahead of print. ABSTRACT PURPOSE: Fabry disease (FD) is a lysosomal storage disease responsible for cochleovestibular involvement. Exact prevalence and pathophysiological mechanisms behind ENT affections are still poorly known. Treating FD with enzyme replacement therapy (ERT) does not seem to significantly improve the ENT symptoms, while the impact of migalastat has yet to be determined. METHODS: We carried out a retrospective multi-centre study on 47 patients from the FFABRY cohort who had an ENT consultation in the context of their FD. The information collected were as follows: clinical examination, videonystagmoscopy, pure-tone speech audiometry, videonystagmography or VHIT (Video Head Impulse Test). Severe hearing loss was defined as greater than 70 dB. RESULTS: The median age of our cohort was 52 years with a non-negligible proportion of n on-classic variants and female carriers. 72.3% of the patients complained of at least one of the following symptoms: hearing loss, tinnitus or vertigo. Pure-tone audiometry was abnormal in 61.7% of the patients (29/47), while speech audiometry was abnormal for 41.7% of the patients. The age of the patients and hypertrophic cardiomyopathy were significantly associated with the existence of an anomaly in pure-tone audiometry results. Severe hearing loss (> 70 dB) was significantly more common in male patients. DISCUSSION: Hearing loss is particularly frequent in FD and is not limited to classic phenotypes. Close ENT follow-up is essential for Fabry patients to detect those who might benefit from hearing aid. Further studies are needed to define the impact of migalastat on cochleovestibular symptoms. PMID:34825971 | DOI:10.1007/s00405-021-07173-x View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Systematic review of epigenetic targets in acute myeloid leukemia

xlomafota13 shared this article with you from Inoreader Systematic review of epigenetic targets in acute myeloid leukemia Via American Journal of Blood Research Am J Blood Res. 2021 Oct 15;11(5):458-471. eCollection 2021. ABSTRACT Acute myeloid leukemia (AML), although genetically and morphologically distinct from other B and T cell ALL subtypes, has one of the most rapidly progressing course and worse outcomes. The current diagnostic classification of AML offers best curative intent, the outcomes are not usually those that are expected at the start of therapy. This is partly attributed to the complex mechanism of leukemogenesis and resistance to chemotherapy. The underlying genetic mechanism of resistance is as complex as is the disease etiopathogenesis. Recent advances in therapy of drug resistant AML highlight the role of epigenetic targets. New FDA approved targeted therapy has also provided some evidence at improving outcomes in clinical trials. This review provides a detailed review of FDA approved targets and ongoing clinical trials for targeting CRISPER, CAR-T and other intestinal moda lities for approach to epigenetictargets. However, this group of epigenetic targeted therapy needs more validation to prove its clinical efficacy. A systematic review of all published research on these targets, investigational agents and FDA approved targeted therapy summarizes this evidence. It also takes us through a brief review of mechanism of action and targets for therapy. PMID:34824880 | PMC:PMC8610793 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.